Kura Oncology (KURA) Stock Price, Quote & News

Company Profile

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabe...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 500 8800

Website: kuraoncology.com

Address:

4930 Directors Place, Suite 500, San Diego, United States

ChessGM Jul. 14 at 1:11 PM

$KURA Get the following news free from edgr.news. Share your stock picks with friends. Access stock selection strategies from prominent hedge funds and proprietary AI models. https://finviz.com/news/367730/kura-oncology-to-present-first-long-term-follow-up-data-further-supporting-darlifarnibs-potential-to-enhance-vegfr-targeted-therapy-in-renal-cell-carcinoma-at-kcrs-2026

0 · Reply

badprecog Jul. 13 at 10:47 PM

$KURA My number 2 bio stock.

1 · Reply

Agingingrace Jul. 10 at 7:18 PM

$KURA why don’t they let this run I mean seriously

0 · Reply

badprecog Jul. 10 at 6:01 PM

$KURA Anyone else math this drug? The numbers I get a embarrassingly large? I would post but I don't want to look like an idiot to people.

3 · Reply

Rubener Jul. 10 at 3:57 PM

$KURA I hope we’ll not wait another 8 months for over $12 😊

0 · Reply

badprecog Jul. 10 at 3:01 PM

$KURA Thanks for the deal.

0 · Reply

badprecog Jul. 9 at 6:19 PM

$KURA So strong!

0 · Reply

BillionerOfKing Jul. 9 at 6:08 PM

$KURA Current Stock Price: $12.11 Contracts to trade: $12.0 KURA Jul 17 2026 Call Entry: $0.30 Exit: $0.56 ROI: 88% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Agingingrace Jul. 9 at 3:49 PM

$KURA when will this finally do something since last year Nov after fda approval it went down from this price range to about 7 to 12 now but it’s been 8 months stuck I mean come on stop the cheerleading

3 · Reply

Flyingkitty Jul. 8 at 12:08 PM

$KURA You can do it !...

1 · Reply

Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib's Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026

Jul 3, 2026, 7:30 AM EDT - 12 days ago

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 12, 2026, 8:00 AM EDT - 4 weeks ago

Kura Oncology Transcript: Status update

Jun 12, 2026, 8:00 AM EDT - 4 weeks ago

Kura Oncology Press release: Status update

Jun 12, 2026, 8:00 AM EDT - 4 weeks ago

Kura Oncology Slides: Status update

Jun 11, 2026, 8:02 AM EDT - 4 weeks ago

Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML

Jun 3, 2026, 3:15 PM EDT - 5 weeks ago

Kura Oncology Transcript: Investor update

Jun 3, 2026, 3:15 PM EDT - 5 weeks ago

Kura Oncology Press release: Investor update

Jun 3, 2026, 3:15 PM EDT - 5 weeks ago

Kura Oncology Slides: Investor update

2026-06-03T11:45:26.000Z - 6 weeks ago

Kura reports data supporting darlifarnib potential for KRAS-mutant cancers

Jun 3, 2026, 6:53 AM EDT - 6 weeks ago

Kura Oncology Highlights Darlifarnib's Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy

Jun 2, 2026, 8:32 AM EDT - 6 weeks ago

Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML

May 26, 2026, 1:30 PM EDT - 7 weeks ago

Kura Oncology Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

May 26, 2026, 8:00 AM EDT - 7 weeks ago

Kura Oncology Proxy statement: Proxy filing

2026-05-26T10:22:44.000Z - 7 weeks ago

Kura Oncology reports first-in-human data from the FIT-001 clinical trial

May 26, 2026, 6:02 AM EDT - 7 weeks ago

Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors

May 19, 2026, 4:02 PM EDT - 2 months ago

Kura Oncology to Present at TD Cowen 7th Annual Oncology Innovation Summit

May 13, 2026, 6:00 PM EDT - 2 months ago

Kura Oncology Transcript: Bank of America Global Healthcare Conference 2026

2026-05-12T21:25:48.000Z - 2 months ago

Kura Oncology reports Q1 EPS (83c), consensus (78c)

May 12, 2026, 4:30 PM EDT - 2 months ago

Kura Oncology Earnings Call Transcript: Q1 2026

May 12, 2026, 4:30 PM EDT - 2 months ago

Kura Oncology Earnings release: Q1 2026

May 12, 2026, 4:30 PM EDT - 2 months ago

Kura Oncology Quarterly report: Q1 2026

May 12, 2026, 4:02 PM EDT - 2 months ago

Kura Oncology Reports First Quarter 2026 Financial Results

May 12, 2026, 4:00 PM EDT - 2 months ago

Kura Oncology Slides: Corporate presentation

2026-05-12T19:13:17.000Z - 2 months ago

Kura, Kyowa Kirin to present updated frontline data from Phase 1 KOMET-007 trial

May 12, 2026, 9:40 AM EDT - 2 months ago

Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress

May 6, 2026, 7:30 AM EDT - 2 months ago

Kura Oncology to Participate in Bank of America Securities Healthcare Conference

May 5, 2026, 7:30 AM EDT - 2 months ago

Kura Oncology to Report First Quarter 2026 Financial Results

Apr 24, 2026, 8:00 AM EDT - 2 months ago

Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML

Apr 17, 2026, 10:30 AM EDT - 3 months ago

Kura Oncology Transcript: Investor Update

Apr 17, 2026, 10:30 AM EDT - 3 months ago

Kura Oncology Press release: Investor Update

Apr 17, 2026, 10:30 AM EDT - 3 months ago

Kura Oncology Slides: Investor Update

2026-04-17T10:06:05.000Z - 3 months ago

Kura Oncology reports results from ongoing FIT-001 clinical trial

Apr 17, 2026, 6:00 AM EDT - 3 months ago

Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib

2026-04-14T11:42:35.000Z - 3 months ago

Kura Oncology initiated with a Buy at Lake Street

Apr 10, 2026, 8:00 AM EDT - 3 months ago

Kura Oncology Proxy statement: Proxy filing

Apr 10, 2026, 8:00 AM EDT - 3 months ago

Kura Oncology Proxy statement: Proxy filing

Apr 9, 2026, 7:30 AM EDT - 3 months ago

Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026

2026-03-30T13:08:09.000Z - 3 months ago

Syndax assumed with a Buy at Jefferies

SNDX

2026-03-24T15:07:11.000Z - 4 months ago

Kura Oncology price target lowered to $25 from $30 at Mizuho

2026-03-13T13:43:20.000Z - 4 months ago

Kura Oncology price target lowered to $15 from $16 at UBS

Mar 12, 2026, 9:00 AM EDT - 4 months ago

Kura Oncology Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 10, 2026, 10:40 AM EDT - 4 months ago

Kura Oncology Transcript: Leerink Global Healthcare Conference 2026

2026-03-06T14:25:12.000Z - 4 months ago

Kura Oncology price target raised to $30 from $29 at BofA

2026-03-06T12:48:51.000Z - 4 months ago

Kura Oncology price target lowered to $36 from $38 at Wedbush

Mar 5, 2026, 8:00 AM EST - 4 months ago

Kura Oncology Earnings Call Transcript: Q4 2025

Mar 5, 2026, 8:00 AM EST - 4 months ago

Kura Oncology Annual report: Q4 2025

Mar 5, 2026, 8:00 AM EST - 4 months ago

Kura Oncology Earnings release: Q4 2025

Mar 5, 2026, 7:00 AM EST - 4 months ago

Kura Oncology Slides: Corporate presentation

2026-03-05T11:36:05.000Z - 4 months ago

Kura Oncology reports Q4 EPS (92c), consensus (49c)

Mar 5, 2026, 6:31 AM EST - 4 months ago

Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 4, 2026, 11:50 AM EST - 4 months ago

Kura Oncology Transcript: TD Cowen 46th Annual Health Care Conference

2026-03-03T18:35:52.000Z - 4 months ago

Kura Oncology management to meet with Citizens

Feb 26, 2026, 7:30 AM EST - 4 months ago

Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results

Feb 25, 2026, 7:30 AM EST - 4 months ago

Kura Oncology to Participate in Three Upcoming Investor Conferences

2026-02-03T11:50:13.000Z - 5 months ago

Kura Oncology price target lowered to $29 from $30 at BofA

Jan 11, 2026, 5:00 PM EST - 6 months ago

Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones

Dec 8, 2025, 12:30 PM EST - 7 months ago

Kura Oncology Transcript: Status Update

Dec 8, 2025, 12:30 PM EST - 7 months ago

Kura Oncology Press release: Status Update

Dec 8, 2025, 12:30 PM EST - 7 months ago

Kura Oncology Slides: Status Update

$Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML$

Dec 8, 2025, 10:30 AM EST - 7 months ago

Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML

$Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia$

Dec 3, 2025, 8:32 AM EST - 7 months ago

Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia

Dec 2, 2025, 8:02 AM EST - 8 months ago

First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin

Nov 25, 2025, 5:16 PM EST - 8 months ago

KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML)

Nov 19, 2025, 10:30 AM EST - 8 months ago

Kura Oncology Transcript: Jefferies London Healthcare Conference 2025

Nov 13, 2025, 12:30 PM EST - 8 months ago

Kura Oncology Transcript: FDA Announcement

Nov 13, 2025, 12:30 PM EST - 8 months ago

Kura Oncology Press release: FDA Announcement

$Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia$

Nov 13, 2025, 10:51 AM EST - 8 months ago

Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

Nov 13, 2025, 10:32 AM EST - 8 months ago

US FDA approves Kura Oncology's blood cancer therapy

Nov 12, 2025, 4:05 PM EST - 8 months ago

Kura Oncology to Participate in Upcoming Investor Conference

Nov 4, 2025, 8:00 AM EST - 9 months ago

Kura Oncology Earnings Call Transcript: Q3 2025

Nov 4, 2025, 8:00 AM EST - 9 months ago

Kura Oncology Quarterly report: Q3 2025

Nov 4, 2025, 8:00 AM EST - 9 months ago

Kura Oncology Earnings release: Q3 2025

Nov 4, 2025, 6:31 AM EST - 9 months ago

Kura Oncology Reports Third Quarter 2025 Financial Results

Nov 3, 2025, 4:02 PM EST - 9 months ago

Kura Oncology Receives Second $30 Million Development Milestone Payment in AML Menin Inhibitor Program With Kyowa Kirin

$Kura Oncology and Kyowa Kirin Announce Presentations of Ziftomenib Ven/Aza Combination Data in Frontline and Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia at 2025 ASH Annual Meeting$

Nov 3, 2025, 9:14 AM EST - 9 months ago

Kura Oncology and Kyowa Kirin Announce Presentations of Ziftomenib Ven/Aza Combination Data in Frontline and Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia at 2025 ASH Annual Meeting

Oct 28, 2025, 4:01 PM EDT - 9 months ago

Kura Oncology to Report Third Quarter 2025 Financial Results

Oct 24, 2025, 7:02 AM EDT - 9 months ago

Kura Oncology Receives $30 Million Development Milestone Payment in Ziftomenib AML Program with Kyowa Kirin

Oct 18, 2025, 1:30 PM EDT - 9 months ago

Kura Oncology Transcript: ESMO Congress 2025

Oct 18, 2025, 1:30 PM EDT - 9 months ago

Kura Oncology Slides: FY 2025

Oct 18, 2025, 3:23 AM EDT - 9 months ago

Kura Oncology Announces Preliminary Data from Its Farnesyl Transferase Inhibitor (FTI) Programs at the 2025 European Society for Medical Oncology (ESMO) Congress

Oct 1, 2025, 2:30 PM EDT - 10 months ago

Kura Oncology Transcript: UBS Virtual Oncology Day

Oct 1, 2025, 7:01 AM EDT - 10 months ago

Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Sep 29, 2025, 4:01 PM EDT - 10 months ago

Kura Oncology and Kyowa Kirin Announce First Patient Dosed in Pivotal Phase 3 KOMET-017 Trial of Ziftomenib for Frontline Acute Myeloid Leukemia (AML)

$Kura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomenib Data in Relapsed/Refractory NPM1-Mutated AML in the Journal of Clinical Oncology$